Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 43 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

NCT05314621
completedphase_4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910
completedphase_4

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821
completedphase_1

Safety and Comfort of AL-4943A Ophthalmic Solution

NCT01326858

Clinical Trials (4)

Showing 4 of 4 trials
NCT05314621Phase 4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Completed
NCT05265910Phase 4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Completed
NCT04708821Phase 4

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Completed
NCT01326858Phase 1

Safety and Comfort of AL-4943A Ophthalmic Solution

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4